What This Document Is
This document is a study guide for the midterm exam in Chamberlain University’s Advanced Pharmacology Fundamentals (NR 565) course. It’s designed to help students review key concepts and prepare for assessment on topics covered in the first two weeks of the course. The guide focuses on legal and ethical considerations for prescribing, pharmacokinetics, and specific drug classifications.
Why This Document Matters
This study guide is essential for NR 565 students preparing for their midterm. It consolidates important information regarding prescriptive authority, drug scheduling, and physiological changes impacting medication effects – all crucial for advanced practice nursing. It’s most useful when used *in conjunction with* course lectures, readings, and other learning materials. This guide exists to help students efficiently focus their study efforts.
Common Limitations or Challenges
This study guide is a *review* tool, not a comprehensive textbook replacement. It highlights key areas but doesn’t provide in-depth explanations of all pharmacological principles. It won’t substitute for a thorough understanding of the course material. Users will still need to consult their textbooks, lecture notes, and other resources for a complete grasp of the concepts.
What This Document Provides
This study guide includes:
* An overview of drug schedules (I-V) and which schedules nurse practitioners can prescribe.
* Definitions and explanations of prescriptive authority and related state regulations.
* Key responsibilities associated with prescribing medications.
* Factors influencing patient medication adherence.
* Guidelines for evidence-based treatment recommendations.
* Physiological changes associated with aging and their impact on pharmacokinetics (absorption, distribution, metabolism, excretion) – including a table summarizing these changes.
* An overview of Beer’s Criteria and medications to avoid in older adults.
* Lists of CYP450 inducers and inhibitors.
* Information on opioid agonists.
* Discussion of poor metabolism phenotypes and their consequences.
* The role of governmental agencies (like the FDA) in prescription drug regulation.
* Black box warnings for pain medications and indicators of potential substance abuse disorder.
This preview *does not* include the full details of black box warnings, specific examples beyond those listed, or comprehensive explanations of all concepts. It also does not contain practice questions or detailed case studies.
